NSE Cuts Nifty Bank Futures Lot Size: Here's How It Impacts Retail Investors
The National Stock Exchange has reduced the market lot size for Nifty Bank futures and options to 15 from 25. The new rule is applicable from the beginning of July 2023 contracts.
What It Means?
This means that only the far-month July and beyond expiry contracts will be revised for market lots. Contracts with maturity of April, May and June will continue to have the existing market lots.
NSE has kept the lot sizes of Nifty 50, Nifty Financial Services, and Nifty Midcap Select unchanged at 50, 40, and 75, respectively.
How Will It Impact Retail Investors?
Reduced market lot size will help boost retail participation in the derivatives segment. In the options market, buyers were missing. From a liquidity perspective, it will improve for Bank Nifty options.
"Do not see a reduction in market lot size for Bank Nifty impacting markets. However, it will benefit traders who are looking to trade in lower quantities and not traders who are trading in higher volumes. The aim of the NSE is to keep the lot size for F&O at 5 lakhs as per their rule book," said Chandan Taparia, head of technical and derivatives research at Motilal Oswal Financial Services Ltd.
The only concern is that Nifty and Bank Nifty will lose the parity they had earlier, as there will be a difference in the value of the lot size of both of these indices. Traders who are doing a pair trade between the same or some sort of arbitrage or hedging may face some concerns, according to Taparia.
Earlier, when the lot size of Nifty Bank was reduced to 25 from 40, there was a sharp increase in retail participation.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.